We are live on ! Find out more
SRPT icon

Sarepta Therapeutics

134 hedge funds and large institutions have $1.29B invested in Sarepta Therapeutics in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 40 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more capital inflows, than outflows

Capital inflows: $309M | Capital outflows: $175M

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

48% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 40

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

5% more funds holding

Funds holding: 128 → 134 (+6)

1.55% more ownership

Funds ownership: 70.86% → 72.41% (+1.6%)

30% less call options, than puts

Call options by funds: $175M | Put options by funds: $250M

Holders
134
Holders Change
+6
Holders Change %
+4.69%
% of All Funds
4.33%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.16%
New
26
Increased
59
Reduced
40
Closed
19
Calls
$175​M
Puts
$250​M
Net Calls
-⁠$75.1​M
Net Calls Change
+$546​K

SRPT Hedge Fund Activity: Q3 2013 in Review

134 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2013, worth a combined $1.29B — up 42% from $904M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new SRPT positions and 19 closed out — a net gain of 7 holders — while 59 added to existing stakes and 40 trimmed.

The largest buyer was SAC Capital Advisors, adding an estimated $35.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $33M.

  • 134 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2013, up from 128 in Q2 2013.
  • Funds reported $1.29B of Sarepta Therapeutics stock for Q3 2013, up 42% quarter-over-quarter.
  • 26 funds opened new Sarepta Therapeutics positions in Q3 2013 and 19 closed out, a net change of +7 holders.
  • The largest Sarepta Therapeutics buyer in Q3 2013 was SAC Capital Advisors, an estimated $35.1M added.
  • The largest Sarepta Therapeutics seller in Q3 2013 was T. Rowe Price Associates, an estimated $33M sold.

Based on aggregated 13F filings for Q3 2013.